Adding Hormone Therapy to PORT Might Not Benefit Patients with Recurrent Prostate Cancer and PSA of 0.5 ng/mL or Less By Ogkologos - March 5, 2026 45 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the POSEIDON meta-analysis of the MARCAP consortium Source RELATED ARTICLESMORE FROM AUTHOR Population-based lung cancer screening can reduce mortality in people who have never smoked, study shows in China Efficacy of Romiplostim In the Treatment and Prevention of Recurrence of Persistent Chemotherapy-Induced Thrombocytopenia FDA Approves Teclistamab in Combination with Daratumumab Hyaluronidase-fihj for Relapsed or Refractory Multiple Myeloma MOST POPULAR FDA Grants Regular Approval to Pembrolizumab and Lenvatinib for Advanced Endometrial... July 23, 2021 Coming Full Circle on Cancer and Extrachromosomal DNA May 10, 2023 Finding New Uses for Targeted Therapies for Cancer: Updates from the... November 9, 2023 EMA Recommends Granting a Conditional Marketing Authorisation for Pemigatinib February 1, 2021 Load more HOT NEWS Opdualag Becomes First FDA-Approved Immunotherapy to Target LAG-3 How MRI add-ons could accelerate the development of new treatments Metastasis Likely Caused by Lack of Oxygen in Cancerous Tumors, Study... Is AI Ready to Play a Leading Role in Colorectal Cancer...
